What checklist should be used to assess a post‑menopausal woman (age 45‑60) before initiating hormone replacement therapy?

Pre-HRT Assessment Checklist for Postmenopausal Women (Age 45-60)

Before initiating hormone replacement therapy in postmenopausal women aged 45-60, systematically assess age/timing criteria, absolute contraindications, cardiovascular and breast cancer risk, and uterine status to determine candidacy and optimal regimen selection. 1

Step 1: Verify Timing Window Eligibility

Age and menopause timing are critical determinants of safety:

• Ideal candidates: Age <60 years OR <10 years since menopause onset 1
• Consider alternative options: Age ≥60 years OR ≥10 years since menopause (significantly increased cardiovascular and dementia risks) 1

Clinical Pearl: The "timing hypothesis" demonstrates that cardiovascular benefits occur only with early initiation, while late initiation (>10 years) substantially increases stroke, MI, and dementia risk 2, 3, 4.

Step 2: Screen for Absolute Contraindications

MHT should be avoided if ANY of the following are present: 1

• Unexplained vaginal bleeding (requires evaluation before any HRT consideration)
• History of breast cancer or endometrial cancer
• Active or recent thromboembolic events: stroke, TIA, MI, PE, DVT/VTE
• Active liver disease

These are non-negotiable contraindications per FDA labeling and Endocrine Society guidelines 1.

Step 3: Assess Cardiovascular Risk Profile

Cardiovascular risk stratification directly determines HRT candidacy and formulation choice: 1

High CVD Risk → Recommend nonhormonal therapies instead of MHT 1

Indicators of high risk:

• Established coronary artery disease
• Prior MI or stroke
• Diabetes with end-organ damage
• Multiple cardiovascular risk factors

Moderate CVD Risk → Transdermal estradiol preferred 1

• Use transdermal estradiol (not oral) with micronized progesterone
• These formulations have less adverse metabolic effects and lower VTE risk 1, 2

Low CVD Risk → Standard MHT appropriate

• Any FDA-approved formulation acceptable 1

Critical distinction: Oral estrogen increases VTE risk; transdermal formulations do not appear to increase VTE risk, particularly when combined with micronized progesterone 5, 2, 6.

Step 4: Evaluate Breast Cancer Risk

Assess baseline breast cancer risk before initiating MHT: 1

• Family history: First-degree relatives with breast cancer
• Personal risk factors: Prior breast biopsies, dense breast tissue, BRCA status if known
• High baseline risk → Consider nonhormonal alternatives 1

Counseling requirement: Inform all patients about possible increased breast cancer risk during and after EPT (estrogen plus progestogen), emphasizing adherence to age-appropriate screening 1. The breast cancer association appears more pronounced with late initiation (>60 years) 3, 4.

Step 5: Exercise Caution in Specific Conditions

These conditions require careful risk-benefit assessment but are not absolute contraindications: 1

• Diabetes mellitus
• Hypertriglyceridemia (>400 mg/dL)
• Active gallbladder disease
• Migraine with aura
• History of endometriosis or fibroids

Step 6: Determine Uterine Status

This determines whether estrogen alone or estrogen plus progestogen is required: 1

Uterus Present:

• Estrogen PLUS progestogen (EPT) mandatory to prevent endometrial hyperplasia and cancer 1
• Options include:
  • Continuous combined regimen (daily estrogen + daily progestogen for amenorrhea)
  • Cyclic regimen (estrogen daily + progestogen 10-14 days/month) 7
  • CEE/bazedoxifene combination (where available) 1

Uterus Absent (post-hysterectomy):

• Estrogen therapy (ET) alone 1
• No progestogen needed

Step 7: Baseline Health Maintenance Assessment

Use the menopause visit as an opportunity to address: 1

• Bone health: Consider baseline DEXA if risk factors present (family history, low BMI, smoking, prior fracture)
• Smoking status: Mandatory cessation counseling (smoking increases VTE risk with HRT)
• Alcohol use assessment
• Age-appropriate cancer screening: Mammography, colonoscopy, cervical cancer screening
• Cardiovascular risk factors: Blood pressure, lipid panel, glucose/HbA1c

Step 8: Laboratory Testing (When Indicated)

Routine hormone testing is NOT required for diagnosis in most cases: 1

• Menopause diagnosis: Based on clinical criteria (menstrual history) 1
• Laboratory confirmation only if: 1
  • Post-hysterectomy without oophorectomy
  • Inadequate menstrual history
  • Then obtain: Replicate FSH and serum estradiol measurements

Step 9: Document Symptom Severity and Treatment Goals

Establish baseline symptom burden to guide treatment decisions:

• Vasomotor symptoms (hot flashes, night sweats) frequency and severity
• Genitourinary syndrome of menopause (vaginal dryness, dyspareunia, urinary symptoms)
• Sleep disturbance
• Mood symptoms (depression, anxiety)
• Quality of life impact

MHT is indicated for bothersome symptoms, not asymptomatic women 1, 2.

Step 10: Shared Decision-Making Discussion

Required counseling elements before prescribing: 1

• Benefits: Most effective treatment for VMS, prevents bone loss, improves genitourinary symptoms 1, 2
• Risks: Small increased stroke risk (persists over time), VTE risk with oral formulations, possible breast cancer risk with long-term EPT 6
• Formulation options and route of administration
• Plan for annual reassessment 1
• Use only FDA-approved preparations (NOT custom-compounded "bioidentical" hormones) 1

---

Common Pitfalls to Avoid

1. Initiating MHT in women >60 years or >10 years post-menopause without compelling indication – substantially increases cardiovascular and dementia risks 3, 4
2. Prescribing estrogen alone to women with intact uterus – dramatically increases endometrial cancer risk 1
3. Using oral estrogen in women with VTE risk factors – transdermal formulations have superior safety profile 1, 2, 6
4. Failing to investigate unexplained vaginal bleeding before HRT initiation – may mask endometrial pathology 1
5. Prescribing custom-compounded hormones – lack FDA oversight and standardized dosing 1